Navigation Links
ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results
Date:3/3/2009

    PARIS, March 4 /PRNewswire-FirstCall/ --

    2008 Key milestones
    - Strong R&D investments, especially in EHT Dx21 and EHT 0202 clinical
      programs:
      - Recruitment of 311 samples achieved for EHT Dx21
      - Start of Phase IIa for EHT 0202 in Alzheimer's disease
    - Expansion of the strategic collaboration with Allergan and extension
      until end 2011

    2008 Key events
    - Appointment of a new Management Board
    - New positioning of Genomic Services and of the SpliceArray(TM) product
      line
    - Repositioning compounds from existing programs to new therapeutic
      indications
    - Issuance of warrants with an exercise period through June 2009

    2009 Outlook
    - Transformation into an emerging healthcare player from an R&D driven
      organization
    - EHT 0202 Phase IIa results available in Q4 2009
    - Expanding EHT 202 program to other CNS indications
    - Initiation of epitope discovery programs for ocular disorders with
      Allergan
    - Preparing for first product launch with EHT Dx21 in Q4 2009
    - Supply of refined biomarker signatures to bioMerieux



    Key figures

                                                 2008          2007
                                             (million EUR) (million EUR)

    Total revenues                                4.2           5.4
    R&D expenses                                  9.9           8.6
    Operating result                            (11.4)         (7.8)
    Net result                                   (8.9)         (7.3)
    Cash burn from operations                     9.6           4.9
    Consolidated cash & cash equivalents at
    Dec. 31                                      21.0          31.3

ExonHit Therapeutics (Alternext: ALEHT) today announced its consolidated financial results for the year ending December 31, 2008.

"2008 was a year of transfor
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. ExonHit is Honoured by the "Innovation Trophy" From The National Institute of Industrial Property (INPI)
2. ExonHit Launches Mouse Genome SpliceArray(TM) for use in Human Disease Modeling Studies
3. Loic Maurel Joins Exonhit Therapeutics to Become CEO
4. ExonHit Launches Rat Genome SpliceArray(TM) Products to Expand High Resolution Gene Expression Profiling for use in Disease Modeling and Toxicogenomics
5. Frederic Desdouits Appointed Member of the Supervisory Board of ExonHit Therapeutics
6. ExonHit Appoints a New Management Board
7. ExonHit Therapeutics - 2007 Financial Results
8. ExonHit Builds A New Organisation
9. ExonHit and bioMerieux Amend Their Strategic Partnership
10. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
11. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... N.J. , June 1, 2015  Novartis ... clinical study of CTL019, an investigational chimeric antigen ... potential in the treatment of specific types of ... conducted by the University of Pennsylvania,s Perelman School ... refractory (r/r) diffuse large B-cell lymphoma (DLBCL) and ...
(Date:6/1/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/9kv3rl/global ... "Global Bioinformatics Market 2015-2019" report to their ... bioinformatics market to grow at a CAGR of ... a field of science that includes computational analysis ... in DNA form and protein sequences in various ...
(Date:6/1/2015)... Ill. , ROCHESTER, Minn. ... June 1, 2015 Baxter Ventures, the venture ... the Mayo Clinic and Velocity Pharmaceutical Development, LLC ("VPD") ... Vitesse is a unique collaboration model initiated by Baxter ... protein-based therapeutics in the areas of immunology, hematology, and ...
(Date:6/1/2015)... 2015   Epic Sciences, Inc. , a private ... to personalize and advance the treatment and management of ... credit under its existing credit facility with Silicon ... available capacity of the facility from $5 million to ... months to April 1, 2019.  The availability of additional ...
Breaking Biology Technology:Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6Global Bioinformatics Market 2015-2019 - Rapid Developments in Molecular Diagnostics 2Global Bioinformatics Market 2015-2019 - Rapid Developments in Molecular Diagnostics 3Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 2Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 3Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 4Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 5Epic Sciences Expands Silicon Valley Bank Credit Facility 2Epic Sciences Expands Silicon Valley Bank Credit Facility 3
... a wealth of new information about single-walled carbon nanotubes through ... the American Chemical Society journal ACS Nano features ... Bruce Weisman to understand how the lengths and imperfections of ... light they emit at near-infrared wavelengths. The researchers found ...
... 31, 2012  Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the ... filed a Certificate of Amendment to its Amended and ... split of its common stock which will take effect ... we believe this is an opportune time to effect ...
... Calif., Jan. 31, 2012   Veracyte, Inc ., a ... cytology, today announced the appointment of Mark Spring as ... that Mark Spring has joined the Veracyte team," said ... extensive experience as a CFO and senior finance leader ...
Cached Biology Technology:Perfect nanotubes shine brightest 2Soligenix Announces 1 for 20 Reverse-Split of its Common Stock 2Soligenix Announces 1 for 20 Reverse-Split of its Common Stock 3Soligenix Announces 1 for 20 Reverse-Split of its Common Stock 4Veracyte Appoints Mark Spring as Chief Financial Officer 2Veracyte Appoints Mark Spring as Chief Financial Officer 3
(Date:5/14/2015)... and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) has announced ... Smart Mobile Devices " report to their offering. ... watershed year for fingerprint sensors in smartphones and tablets, ... fingerprint sensors a raison d,etre in the mobile milieu ... must-have feature in flagship smartphones. The key ...
(Date:5/11/2015)... 2015  Synaptics Incorporated (NASDAQ: SYNA ), ... announced the appointment of Wajid Ali ... reporting to Rick Bergman , President and ... Officer, Kathleen Bayless , who announced her ... Ali brings extensive financial management expertise to Synaptics, ...
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
Breaking Biology News(10 mins):Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... grapes slow what,s for many Americans a downhill sequence of ... and type 2 diabetes? Scientists at the University ... effect of grapes in reducing risk factors related to cardiovascular ... due to phytochemicals -- naturally occurring antioxidants that ...
... know that eating a calcium-rich diet is important for ... clearly on display in any elementary school cafeteria where ... icons encouraging children to make sure they drink milk ... children to pay attention to their dairy intake might ...
... Studies led by Stony Brook University professor of chemistry ... time a drug remains bound to its target, or ... agents. Tonge will present these results at ... meeting in a talk titled "Slow Onset Inhibitors of ...
Cached Biology News:Grapes reduce risk factors for heart disease and diabetes, U-M animal study shows 2Grapes reduce risk factors for heart disease and diabetes, U-M animal study shows 3Study suggests a much earlier onset for bone problems 2Study suggests a much earlier onset for bone problems 3Lengthening time a drug remains bound to a target may lead to improving diagnostics, therapy 2
384 Cluster Tube Racks...
Request Info...
Unique enzyme blend containing Taq and Pwo DNA Polymerase and another thermostable enzyme. The Expand 20 kbPLUS PCR System also includes an optimized reaction buffer, MgCl2 solution, and a human cont...
... The EC105 power supply is a highly compact, ... A single adjustment knob and one hi-lo range ... 10 volt increments from 20 to 250 volts. ... from indicating output voltage to output current. For ...
Biology Products: